Optimal Management of Early-Stage HCC

Video

Key Takeaways:

The importance of multidisciplinary management of the underlying liver disease and function as well as the tumor burden in patients with hepatocellular carcinoma (HCC).

Solidifying interactions among locoregional practitioners, interventional radiologists, medical oncologists, and hepatologists to help define when to cease TACE (transarterial chemoembolization) and start a patient on systemic therapy.

Triggers to discontinue locoregional therapy and move to systemic therapy.

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Manish A. Shah, MD
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,
John Michael Bryant, MD,
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Efrat Dotan, MD, Fox Chase Cancer Center
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers